Medicare Negotiation

Politics Rachel Cohrs

In a momentous vote for Pelosi, House sends drug pricing reforms to President Biden’s desk

Politics Rachel Cohrs

Here’s who Democrats’ drug pricing bill will actually help

Matt's Take Matthew Herper

The Senate’s drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences

Politics Rachel Cohrs

In a massive victory for Democrats, Medicare is poised to negotiate drug prices

Politics Nicholas Florko

Powerful Senate Democrat outlines ‘plenty’ more drug pricing reforms to follow Medicare negotiation

Politics Rachel Cohrs

Insulin giants Eli Lilly and Novo Nordisk boosted their lobbying spending as Democrats eyed pricing reform

Exclusive Rachel Cohrs

How Nancy Pelosi almost killed drug pricing reform — a gamble that expanded Democrats’ final deal

Politics Rachel Cohrs

Here’s who wins and loses in Democrats’ new prescription drug pricing deal

Politics Lev Facher and Rachel Cohrs

Democrats circulate a new drug pricing outline with a big carveout for small biotechs

Politics Nicholas Florko and Rachel Cohrs

Here’s where Democrats’ resurrected drug pricing talks are headed

Politics Lev Facher

Here’s how Biden can address high drug prices, without help from Congress

Politics Rachel Cohrs

Pelosi working to gather support for last-minute, last-ditch drug pricing policy

Politics Rachel Cohrs

Biden abandons his push to lower drug prices

Politics Rachel Cohrs

The four senators who could make or break Democrats’ drug pricing ambitions

Politics Nicholas Florko

Underpinning Sinema’s outspoken opposition to major drug pricing reforms: her close ties to Arizona biotechs

Exclusive Rachel Cohrs and Nicholas Florko

Key Senate committee considers a carveout for small biotech companies in drug pricing reforms

Politics Rachel Cohrs and Nicholas Florko

In May, 10 moderate Democrats opposed major drug pricing reform. Ahead of a key vote, that list is shrinking

Politics Rachel Cohrs

Medicare negotiation

Most Read

Democrats dramatically narrow their ambitions for lowering insulin costs

Democrats will have to limit their drug pricing reforms to Medicare to comply with Senate rules

The view on drug pricing from Wall Street, a pharma-friendly Dem holds firm, and what’s next for a big telehealth bill

‘What can we do?’: Pharma lobbyists face their biggest test in a decade, as Democrats barrel toward a vote on drug pricing

Biden tells Dems to quickly pass pared-down economic package

Democrats tweak their drug pricing plan in last-ditch effort to pass reforms

Three years after the Senate grilled drugmakers … nothing’s changed

What does the Build Back Better Act actually mean for the health care industry?

All Coverage

In a momentous vote for Pelosi, House sends drug pricing reforms to President Biden’s desk

Here’s who Democrats’ drug pricing bill will actually help

The Senate’s drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences

In a massive victory for Democrats, Medicare is poised to negotiate drug prices

Powerful Senate Democrat outlines ‘plenty’ more drug pricing reforms to follow Medicare negotiation

Insulin giants Eli Lilly and Novo Nordisk boosted their lobbying spending as Democrats eyed pricing reform

How Nancy Pelosi almost killed drug pricing reform — a gamble that expanded Democrats’ final deal

Here’s who wins and loses in Democrats’ new prescription drug pricing deal

Democrats circulate a new drug pricing outline with a big carveout for small biotechs

Here’s where Democrats’ resurrected drug pricing talks are headed

Here’s how Biden can address high drug prices, without help from Congress

Pelosi working to gather support for last-minute, last-ditch drug pricing policy

Biden abandons his push to lower drug prices

The four senators who could make or break Democrats’ drug pricing ambitions

Underpinning Sinema’s outspoken opposition to major drug pricing reforms: her close ties to Arizona biotechs

Key Senate committee considers a carveout for small biotech companies in drug pricing reforms

In May, 10 moderate Democrats opposed major drug pricing reform. Ahead of a key vote, that list is shrinking

Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day